Image

Global Statin Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Statin Market, By Type (Synthetic Statins, Natural Statins), Drug Class (Atorvastatin, Fluvastatin, Lovastatin, Rosuvastatin, Simvastatin, and Pitavastatin), Application (Cardiovascular Diseases, Lifestyle Diseases, Others), End User (Hospitals, Clinics and Others) – Industry Trends and Forecast to 2029.

Statin Market

Global Statin Market Analysis and Size

High cholesterol in the body can promote a wide number of diseases in the body. High levels of cholesterol in individuals can invite heart problems owing to the development of fatty deposits in the blood vessels. To lower the cholesterol, numerous pharmaceutical drugs are available in the market. Statin is one of them.                                         

  • Data Bridge Market Research analyses that the statin market is expected to undergo a CAGR of 4.20% during the forecast period. This indicates that the market value, which was USD 14.69 billion in 2021, would rocket up to USD 20.41 billion by 2029. “Hospitals” dominates the end user segment of the statin market owing to the rising requirement for treatment of cardiovascular disorders and inflammatory disorders treatments. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Statin Market Definition

Statins are the pharmaceutical drugs that are given to the patients to lower the level of cholesterol in their body. Statins lower down the low density lipoprotein cholesterol in the body and can be consumed by both high risk patients and patients already suffering from the ill effects of high cholesterol.             

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Synthetic Statins, Natural Statins), Drug Class (Atorvastatin, Fluvastatin, Lovastatin, Rosuvastatin, Simvastatin, and Pitavastatin), Application (Cardiovascular Diseases, Lifestyle Diseases, Others), End User (Hospitals, Clinics and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

AstraZeneca (UK), Pfizer Inc. (US), Merck Sharp & Dohme Corp. (Germany), Aurobindo Pharma. (India), Amgen Inc. (US), GlaxoSmithKline plc (UK), Biocon (India), Concord Biotech (India), Novartis AG (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher. (US), BD (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific, Inc. (US), bioMérieux S.A. (France),  DiaSorin S.p.A (Italy), AccuBioTech Co., Ltd. (China), Meridian Bioscience (US), Biocartis Bioscience (Europe), GeneSTAT Molecular Diagnostics, LLC (US), Terumo Corporation (Japan) and Grifols, S.A (Spain)   

Market Opportunities

  • Growth in the awareness about the benefits of cholesterol lowering drugs
  • Increasing rate of high cholesterol in patients
  • Rising research and development opportunities

Statin Market Dynamics

Drivers

  • Rising prevalence of obesity

Growing population base of overweight and obese individuals globally is one of the major factor fostering the growth of the market. India, Germany, China, United States and United Kingdom have the highest obese population base in the world. Obesity gives rise to numerous problems in the body. Respiratory problems, diabetes and, high cholesterol levels other chronic and acute diseases are some of the examples. According to studies, statins have reduced heart attacks and strokes by 25% to 35%.       

  • Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted to provide best of the medications is also bolstering the market growth rate.

  • Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, rising awareness about the negative impact of obesity on the body, growing prevalence of acute and chronic diseases, rising geriatric population base and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, unhealthy lifestyle of individuals, rising internet penetration rate, growing number of cardiovascular diseases and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges Global Statin Market

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities, uneven distribution of medical services, an expansion in need for adequate remedy options and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, cultural and commercial agents coupled with side effects of statins, limited insurance coverage and regulatory compliance, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This statin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the statin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Statin Market

COVID-19 had a negative impact on the market. The supply chain disruptions created challenges for the transportation and distribution of drug delivery systems and equipment. Also, restrictions imposed on the movement further created hindrances. Subsequent fall in the demand and supply of non- important medical devices and equipment further created hindrances for the market. However, owing to the rising number of patients on daily basis and large number of treatment procedures on hold, there is a huge scope of growth post the pandemic.   

Global Statin Market Scope

The statin market is segmented on the basis of type, drug class, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Synthetic Statins
  • Natural Statins

On the basis of type, the statin market is segmented into natural statins and synthetic statins. 

Drug class

  • Atorvastatin
  • Fluvastatin
  • Lovastatin
  • Rosuvastatin
  • Simvastatin
  • Pitavastatin

On the basis of drug class, the statin market is segmented into atorvastatin, fluvastatin, lovastatin, rosuvastatin, simvastatin, and pitavastatin. Atorvastatin is further sub-segmented as lipitor and others. Fluvastatin is fragmented into lescol, canef, and vastin. Lovastatin is divided into mevacor and others. Pravastatin is categorized into pravacho. Rosuvastatin is classified into crestor. Simvastatin is termed as Zocor. Pitavastatin is phrased as livalo.

Application

  • Cardiovascular Diseases
  • Lifestyle Diseases
  • Others

On the basis of application, the statin market is segmented into cardiovascular diseases, lifestyle diseases, and others. Cardiovascular diseases are further sub-fragmented into heart strokes and attacks. On the basis of lifestyle diseases the market is sub-segmented into obesity, diabetes, and inflammation.

End users

  • Hospitals
  • Clinics
  • Others

On the basis of end user, the statin market is branched into hospitals, clinics and others.

Statin Market Regional Analysis/Insights

The statin market is analysed and market size insights and trends are provided by country, type, drug class, application and end user as referenced above.

The countries covered in the statin market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the statin market because of the strong base of healthcare facilities, widespread utilization of medications, surging occurrences of chronic diseases such as obesity, high cholesterol, diabetes and heart attacks and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, increasing health conscious people within the region, rise in cases of cardiovascular diseases and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The statin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for statin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the statin market. The data is available for historic period 2010-2020.

Competitive Landscape and Statin Market Share Analysis

The statin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to statin market.

Some of the major players operating in the statin market are:

  • AstraZeneca(UK)
  • Pfizer Inc. (US)
  • Merck Sharp & Dohme Corp. (Germany)
  • Aurobindo Pharma. (India)
  • Amgen Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Biocon (India)
  • Concord Biotech (India)
  • Novartis AG (Switzerland)
  • Abbott (US)
  • Siemens Healthineers AG (Germany)
  • Quidel Corporation (US)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Danaher. (US)
  • BD (US)
  • Chembio Diagnostics (US)
  • EKF Diagnostics (UK)
  • Trinity Biotech plc (Ireland)
  • Instrumentation Laboratory (US)
  • Nova Biomedical (US)
  • PTS Diagnostics (US)
  • Sekisui Diagnostics (US)
  • Thermo Fisher Scientific, Inc. (US)
  • bioMérieux S.A. (France)
  • DiaSorin S.p.A (Italy)
  • AccuBioTech Co., Ltd. (China)
  • Meridian Bioscience (US)
  • Biocartis Bioscience (Europe)
  • GeneSTAT Molecular Diagnostics, LLC (US)
  • Terumo Corporation (Japan)
  • Grifols, S.A (Spain)  

Research Methodology : Global Statin Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-statin-market

Customization Available : Global Statin Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Statin Market will be projected at USD 20.41 billion during the forecast by 2029.
The Statin Market is Projected to Grow at a CAGR of 4.20% During the Forecast Period of 2022 to 2029.
AstraZeneca (UK), Pfizer Inc. (US), Merck Sharp & Dohme Corp. (Germany), Aurobindo Pharma. (India), Amgen Inc. (US), GlaxoSmithKline plc (UK), Biocon (India), Concord Biotech (India), Novartis AG (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher. (US), BD (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific, Inc. (US), bioMérieux S.A. (France), DiaSorin S.p.A (Italy), AccuBioTech Co., Ltd. (China), Meridian Bioscience (US), Biocartis Bioscience (Europe), GeneSTAT Molecular Diagnostics, LLC (US), Terumo Corporation (Japan) and Grifols, S.A (Spain) are the Major Companies Operating in Statin Market.
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The Statin Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.